Definition of clinically relevant non‐major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non‐surgical patients: communication from the SSC of the ISTH - Kaatz - 2015 -
Rivaroxaban for cancer-associated venous thromboembolism - Bo Liang, Yi Liang, Li-Zhi Zhao, Yu-Xiu Zhao, Ning Gu, 2021
Clinically relevant non-major bleeding and intra-cranial haemorrhage in... | Download Scientific Diagram
Anthos Therapeutics' Novel Dual-Acting Factor XI/XIa Inhibitor, Abelacimab 150 mg, Demonstrated a 67%
Nephrology Journal Club on X: "T1h: Outcomes were defined accordingly with International Society on Thrombosis and Haemostasis @isth #NephJC https://t.co/b0tQMjYKbE" / X
Efficacy and safety of direct oral anticoagulants for secondary prevention of cancer associated thrombosis: a meta-analysis of randomized controlled trials | Scientific Reports
Anticoagulation strategies and clinical outcomes after bleeding events during anticoagulation therapy for venous thromboembolism in the practice-based Japanese registry | Journal of Thrombosis and Thrombolysis
Direct Oral Anticoagulants: A User's Guide | Consultant360
Incidence of major and clinically relevant non-major bleeding in patients prescribed rivaroxaban for stroke prevention in non-valvular atrial fibrillation in secondary care: Results from the Rivaroxaban Observational Safety Evaluation (ROSE) study
Cost–utility analysis of apixaban compared with usual care for primary thromboprophylaxis in ambulatory patients with cancer | CMAJ
Abstract 12434: Long-Term Clinical Outcomes After Major versus Minor Bleeding in Patients With Atrial Fibrillation: The Fushimi AF Registry | Circulation
PACIFIC-AF: Low bleeding rates for asundexian in atrial fibrillation - Medical Conferences
WarfarinApixaban Primary outcome: major/clinically relevant bleeding (through 6 months) Secondary objective: Death, MI, stroke, stent thrombosis Randomize. - ppt download
Characterization of Major and Clinically Relevant Non-Major Bleeds in the APEX Trial
MASTER DAPT | Terumo Interventional Systems
Identification of International Society on Thrombosis and Haemostasis major and clinically relevant non-major bleed events from electronic health records: a novel algorithm to enhance data utilisation from real-world sources | International Journal
New strategies for effective treatment of vitamin K antagonist‐associated bleeding - ScienceDirect
Renal function and clinical outcome of patients with cancer-associated venous thromboembolism randomized to receive apixaban or dalteparin. Results from the Caravaggio trial | Haematologica
Therapeutic Strategies Following Major, Clinically Relevant Nonmajor, and Nuisance Bleeding in Atrial Fibrillation: Findings From ORBIT‐AF | Journal of the American Heart Association
Frontiers | Apixaban for Primary Prevention of Venous Thromboembolism in Patients With Multiple Myeloma Receiving Immunomodulatory Therapy
A Phase IV Study of Thromboembolic and Bleeding Events Following Hip and Knee Arthroplasty Using Oral Factor Xa Inhibitor - ScienceDirect
Anthos' Blood Thinner Abelacimab Outperforms Rivals in Safety by 67% in AF Patients
PPT - John H. Alexander, MD, MHSc Duke Clinical Research Institute, Durham, NC, USA Lars Wallentin, MD, PhD Uppsala Clinical R PowerPoint Presentation - ID:154927
Management and outcomes of vaginal bleeding and heavy menstrual bleeding in women of reproductive age on direct oral anti-factor Xa inhibitor therapy: a case series - The Lancet Haematology
JCM | Free Full-Text | Effectiveness and Safety of Apixaban vs. Warfarin in Venous Thromboembolism Patients with Obesity and Morbid Obesity
Non-major bleeding risk of direct oral anticoagulants versus vitamin K antagonists for stroke prevention with atrial fibrillation: a systematic review and network meta-analysis | European Journal of Clinical Pharmacology
Cancers | Free Full-Text | A Phase II Study to Compare the Safety and Efficacy of Direct Oral Anticoagulants versus Subcutaneous Dalteparin for Cancer-Associated Venous Thromboembolism in Patients with Advanced Upper Gastrointestinal,
